Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool December 13, 2004 Charly Travers	PDL Rakes It In A robust revenue stream combined with an exciting drug pipeline is this biotech's recipe for success.
The Motley Fool March 22, 2005 Travers & Djuranovic	Stock Madness 2005: Protein Design Labs vs. Taser One keeps you healthy; the other keeps you safe. But which one will make your portfolio happier? "Stock Madness 2005," a contest based loosely on the annual NCAA College Basketball Tournament, a.k.a. March Madness shows the way.
The Motley Fool August 5, 2005 Charly Travers	No Surprise Over PDL's Upside Protein Design Labs' overwhelmingly positive earnings release is good news for shareholders.
The Motley Fool March 30, 2005 Travers & Smith	Stock Madness 2005: Protein Design Labs vs. Plum Creek Timber This biotech isn't as risky as you might think. But is it as solid as a tree company? Find out in "Stock Madness 2005," a contest based loosely on the annual NCAA College Basketball Tournament, a.k.a. March Madness.
The Motley Fool May 3, 2005 Charly Travers	PDL's Well-Stocked Pipeline A broad drug portfolio makes this biotech, Protein Design Labs, a long-term winner.
The Motley Fool January 28, 2005	Netflix Exclusive on Fool Radio How does Netflix feel about the competition?
The Motley Fool January 6, 2006 Roger Friedman	Super Bowl Stocks Whether it's the NFL or your equity portfolio, success follows talented leaders. Think about your watch list. Have you studied the qualitative factors of your stocks?
The Motley Fool March 28, 2005 Charly Travers	Stock Madness 2005: Protein Design Labs vs. Yahoo! Two very different Rule Breakers face off in "Stock Madness 2005," a contest based loosely on the annual NCAA College Basketball Tournament, a.k.a. March Madness.
The Motley Fool July 14, 2005 Charly Travers	Dueling Fools: Protein Design Labs Bull Protein Design Labs is a great company for biotech investors. It has a diverse and growing revenue stream, will turn cash-flow positive next year, and has some potential winners in its pipeline to increase the company's value for long-term-minded shareholders.
The Motley Fool February 3, 2005	Netflix Battles the Skeptics Netflix CEO Reed Hastings sat down for a conversation to discuss the company's past, present, and future. This is the third of four parts.
The Motley Fool January 31, 2005	How Netflix Maintains Growth Netflix CEO Reed Hastings sat down for a conversation to discuss the company's past, present, and future. This is the first of four parts.
The Motley Fool December 30, 2004 Paul Elliott	Why Daddy Loves This Stock Investing a friend's hard-earned money can be every bit as unnerving as investing your own. Let's take a look at Protein Design Labs, the leader in antibody humanization technology.
The Motley Fool February 2, 2005	What Is Netflix's Greatest Threat? Netflix CEO Reed Hastings sat down for a conversation to discuss the company's past, present, and future. This is the third of four parts.
The Motley Fool March 30, 2005 Charly Travers	Stock Madness 2005: Celgene vs. Netflix Biotech battles entertainment in this Round 3 matchup of "Stock Madness 2005," a contest based loosely on the annual NCAA College Basketball Tournament, a.k.a. March Madness.
The Motley Fool August 16, 2005 Roger Friedman	Adrenaline Stocks With just a small portion of your portfolio, high-growth stocks can supercharge your returns.
Inc. December 2005 Patrick J. Sauer	Q&A: Reed Hastings, Netflix Reed Hastings, the founder of Netflix, talks about developing a passion brand, and sustaining it as passions change.
The Motley Fool March 15, 2005 Charly Travers	PDL Eyeing Up Profits A timely acquisition is paying off for this drug maker. Investors, take note.
The Motley Fool March 24, 2005 Munarriz & Simpson	Stock Madness 2005: Netflix vs. Harley-Davidson Will DVD rentals or motorcycles prove to be more popular? Check out "Stock Madness 2005," a contest based loosely on the annual NCAA College Basketball Tournament, a.k.a. March Madness to find out.
The Motley Fool October 18, 2004 Rick Aristotle Munarriz	Big, Bad Amazon Netflix was doing just fine until Amazon decided to crash its party. Netflix shares surrendered a little more than 40% of their value.
The Motley Fool April 21, 2005 John Reeves	Blowing Away the Average Archipelago Holdings proves you can't always play the odds if you want to beat the market.
The Motley Fool November 30, 2004 Charly Travers	Picking Biotech's Winners Doing well as a biotech investor comes as much from avoiding the losers as picking the winners. A quick screen for making winning investment picks.
The Motley Fool March 18, 2005 Munarriz & Hwang	Stock Madness 2005: Netflix vs. Overstock Two online powerhouses fight to progress to Round Two of "Stock Madness 2005," a contest based loosely on the annual NCAA College Basketball Tournament, a.k.a. March Madness.
The Motley Fool January 25, 2005 Charly Travers	Grading Old-School Biotech Be very wary of biotech IPOs from companies lacking drugs.
The Motley Fool August 4, 2004 Charly Travers	Labs' Report Offers Mixed Results TProtein Design Labs' royalty intake looks great, but its drug development does not.
The Motley Fool April 5, 2004 W.D. Crotty	The Fight for Video on Demand Netflix sizes up a hot market that could pose a threat to it.
The Motley Fool November 2, 2005 Marko Djuranovic	Netflix Adds Ads The company is allowing outside advertising in its red mailers, but the stock is still overvalued.
The Motley Fool January 26, 2005 Tim Beyers	The Rules of Rule Breaking The next ultimate growth stock is out there. Here is how to find it.
The Motley Fool November 10, 2005 Rick Aristotle Munarriz	Why I'm Not Selling Netflix You shouldn't hold shares with eyes shut and fists clenched, and if you see the company's dynamic deteriorate to the point where it has been damaged irreparably, it's time to bolt. But don't base that on some line in the valuation sand.
The Motley Fool December 15, 2004 Marko Djuranovic	It's Good to Be Right Blockbuster's latest move is an admirable attempt to save an ailing company but, ultimately, of little interest to Netflix investors.
The Motley Fool May 23, 2005 Marko Djuranovic	Is Netflix Settling for Wal-Mart? Though it looks great on paper, the deal could be trouble. Amazon.com is the real partner of value in this race. Investors, take note.
The Motley Fool April 4, 2005 Rick Aristotle Munarriz	Stock Madness 2005: Netflix vs. PetroKazakhstan It's risky business when an online movie rental company takes on a Kazakh oil firm in "Stock Madness 2005," a contest based loosely on the annual NCAA College Basketball Tournament, a.k.a. March Madness.
The Motley Fool July 24, 2007 Rick Aristotle Munarriz	Red Mailers, Blue Investors Dark days are ahead for Netflix, but things could be worse. The combined market cap of Netflix and Blockbuster is less than the $2 billion market cap that Netflix alone commanded at its peak seven months ago. Investors, take note.
The Motley Fool November 30, 2004 Tim Beyers	Ripe Rule Breaker? Apple's stock has gone too far, too fast, and now it appears poised for an awfully messy fall.
The Motley Fool April 21, 2006 Rich Smith	Foolish Forecast: Nudging Netflix With its stock price now up more than 150% over the last year, can Netflix possibly go higher?
The Motley Fool September 22, 2005 Rich Smith	Dueling Fools: Netflix Bear Shouldn't growth stocks actually grow? If you assume that most Netflix subscribers are also cable subscribers, they, too, must realize that Netflix offers them little more than the chance to pay twice to see a movie that will be broadcast "free" on cable shortly. Investors, beware.
The Motley Fool April 28, 2009 Rick Aristotle Munarriz	7 Questions for Netflix CEO Reed Hastings The entertainment visionary talks about the state of home video.
The Motley Fool December 23, 2010 Anders Bylund	2010 in Review: Netflix Netflix is expected to close the year with about 20 million subscribers and a very different set of challenges and opportunities than last year's. Can the stock keep climbing in 2011 or is CEO Hastings flying too close to the sun already?
The Motley Fool November 16, 2004 Charly Travers	Finding Biotech's 50-Baggers Finding these superb biotechs isn't a search for a once-in-a-lifetime opportunity. These great investments pop up a lot more frequently than you may think.
The Motley Fool November 5, 2007 Mac Greer	Fool Video: Does Netflix Need Blockbuster? Is Blockbuster's loss really Netflix's gain? Does Netflix need Blockbuster? These questions are answered in this video.
The Motley Fool January 23, 2009 Anders Bylund	Foolish Forecast: There's Movie Magic in Netflix In advance of earnings, let's take a look at some of Netflix's peers and competitors.
The Motley Fool January 12, 2005 Charly Travers	Forget Earnings; Think R&D Look at the big picture to find biotech companies with the most promise.
The Motley Fool January 2, 2004 W.D. Crotty	Netflix's Swelling Competition The first-mover finds itself facing a watershed of competition.
The Motley Fool September 23, 2005 Marko Djuranovic	Why I'm Selling Netflix At a hefty 30 times 2006 earnings, the company looks mighty pricey. A great company is not the same thing as a great investment opportunity.
The Motley Fool February 1, 2005	New Avenues for Netflix? Netflix CEO Reed Hastings sat down for a conversation to discuss the company's past, present, and future. This is the second of four parts.
The Motley Fool January 3, 2006 Rick Aristotle Munarriz	What Netflix Needs in 2006 The push for online video game rentals will test Netflix in the year ahead. Investors, take note.
The Motley Fool July 14, 2005 Stephen D. Simpson	Dueling Fools: Protein Design Labs Bear Protein Design Labs could be a big winner, or a major loser. The biotech has a strong business, but today's stock price isn't "great."
The Motley Fool May 21, 2004 Charly Travers	Protein Design Labs' Mixed Results Protein Design Labs' Nuvion looks like a winner, while other drugs stumble. Nuvion is in early clinical development for the treatment of severe ulcerative colitis and so far the results seem particularly compelling.
The Motley Fool February 13, 2006 Rick Aristotle Munarriz	Genie in a Throttle Netflix is turning the cold shoulder to its more active accounts. To ease defections, the company will either have to be more transparent in its throttling or institute a cap on its rentals. Investors, watch this situation closely.
The Motley Fool April 24, 2009 Rick Aristotle Munarriz	Reed Hastings Opens the Red Envelope Netflix's CEO discusses the company's monster quarter and the DVD rental specialist's future.
The Motley Fool April 1, 2004 Alyce Lomax	Nuts Over Netflix? Netflix shares jumped today after the company said it has 84% more subscribers than it had this time last year.